Abstract
Systemic lupus erythematosus is an autoimmune disease associated with an aberrant production of autoantibodies by self-reactive B lymphocytes. The study of the phenotypic characteristics of B lymphocytes and the identification of their surface receptors such as BAFF-R, TACI and BCMA, which are responsible of their survival and maturation, have contributed to the development of new therapeutic strategies in recent years.
Keywords:
B lymphocyte; B-cell activation factor; Biologic therapies; Linfocito B; Lupus eritematoso sistémico; Systemic lupus erythematosus; Tratamientos biológicos.
Copyright © 2014 Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use
-
Antigens, CD20 / immunology
-
B-Cell Activation Factor Receptor / antagonists & inhibitors
-
B-Cell Activation Factor Receptor / immunology
-
B-Cell Maturation Antigen / antagonists & inhibitors
-
B-Cell Maturation Antigen / immunology
-
B-Lymphocytes / immunology
-
B-Lymphocytes / pathology*
-
Cell Survival
-
Forecasting
-
Humans
-
Immunophenotyping
-
Lupus Erythematosus, Systemic / drug therapy*
-
Lupus Erythematosus, Systemic / immunology
-
Lupus Erythematosus, Systemic / pathology
-
Lymphopoiesis
-
Molecular Targeted Therapy
-
Sialic Acid Binding Ig-like Lectin 2 / antagonists & inhibitors
-
Sialic Acid Binding Ig-like Lectin 2 / immunology
-
Transmembrane Activator and CAML Interactor Protein / antagonists & inhibitors
-
Transmembrane Activator and CAML Interactor Protein / immunology
Substances
-
Antibodies, Monoclonal
-
Antigens, CD20
-
B-Cell Activation Factor Receptor
-
B-Cell Maturation Antigen
-
CD22 protein, human
-
Sialic Acid Binding Ig-like Lectin 2
-
TNFRSF13B protein, human
-
TNFRSF13C protein, human
-
TNFRSF17 protein, human
-
Transmembrane Activator and CAML Interactor Protein